Robert Bradway
📊 CEO Reputation Score
FY2025 vs FY2024 · Source: SEC EDGAR filings- Free cash flow: $10.4B → $8.1B (−22.1% YoY) — fiscal 2025 vs fiscal 2024
- Profit (net income): $4.1B → $7.7B (+88.5% YoY) — fiscal 2025 vs fiscal 2024
🧭 Personal Philosophy & Quotes
Bradway runs Amgen like the banker he was, in service of the science he funds: patent cliffs are a fact of life, so the only durable strategy is a pipeline of medicines with 'very big effect sizes' for serious disease — plus the financial engineering (biosimilars, buybacks, disciplined deals) to fund it. His recurring argument to society and payers is reciprocal: reward profound innovation and it will keep coming. For investors, that makes him a capital-allocation CEO whose bet is concentrated in a handful of late-stage assets, above all in obesity and cardiovascular disease.
Operating principles
- Innovate or die — pipelines replace patents
- Chase profound effect sizes, not incremental ones
- Prove innovation's value to society, relentlessly
“We like to say at Amgen, 'innovate or die'.”— Morgan Stanley 'Exceptional Leaders / Exceptional Ideas' interview, Sep 2022
“We need profound, not incremental, innovation.”— 'Business of Biotech' conference keynote, Moffitt Cancer Center
Overview
A biologist by first degree and a Morgan Stanley managing director by career, Bradway arrived at Amgen as a finance hire in 2006 and was CEO within six years. Fourteen years on he is one of biotech's longest-serving chiefs, having steered Amgen through patent expiries on its founding drugs into biosimilars, genetics-led discovery and the obesity race.
Education
- B.A. Biology — Amherst College
- MBA — Harvard Business School
Personal Likes & Life
- Chairs the CEO Roundtable on Cancer; sits on Boeing's board and USC's board of trustees
- Received an honorary doctorate from Keck Graduate Institute (2025) for leadership in applied life sciences
- A former investment banker who still frames pipeline decisions in return-on-capital language
Past Experience
Healthcare investment banker in New York; from 2001 a managing director running the European banking and corporate finance business from London.
Vice President, Operations Strategy; EVP & CFO from 2007 to 2010.
Joins the board in Oct 2011; named CEO in May 2012.
Adds the chairmanship; leads the deCODE, Onyx, BeiGene and Horizon deal eras.
🏆 Achievements
- Grew revenue from ~$17bn (2012) to over $30bn while replacing the patent-expired first generation of Amgen blockbusters
- Bought deCODE Genetics (2012) — making human genetics a core discovery engine years before it was fashionable
- Horizon Therapeutics acquisition (2023, ~$27.8bn) added a rare-disease growth engine; Amgen became a top-tier obesity contender with MariTide
🎙️ Interviews to Watch / Read
Amgen / Morgan Stanley — 'Innovate or Die' interview with Bob Bradwayhttps://wwwext.amgen.com/stories/2023/01/innovate-or-die-says-bob-bradway-in-interview-with-morgan-stanley ↗PharmaBoardRoom — Four insights from Amgen CEO Bob Bradway (Money Maze podcast)
https://pharmaboardroom.com/articles/four-insights-from-amgen-ceo-bob-bradway/ ↗
⚠️ Failures & Setbacks
- The $27.8bn Horizon deal drew an FTC challenge and a long closing fight — the price of his biggest bet was fully tested before it closed
- Kyprolis (from the $10.4bn Onyx deal, 2013) never became the mega-blockbuster its price implied
- Amgen's early obesity data (2024) triggered sharp sell-offs when investors judged effect sizes and tolerability against Lilly and Novo standards